{"title":"Progress in treatment of MLL-rearranged leukemia in children","authors":"Z. Gu, J. Xia, Tian-yu Li","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.02.014","DOIUrl":null,"url":null,"abstract":"MLL-rearranged leukemia is caused by rearrangement of the MLL gene located on chromosome 11q23, which is one of the common types in childhood leukemia. It can be clinically manifested as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome, and treatment-related leukemia. At present, the treatments of MLL-rearranged leukemia are combined chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT). The survival rate has been improved, but the outcomes and prognosis of most MLL-rearrangement leukemia are not excellent. Targeted therapy and immunotherapy are expected to become new treatments for the disease, which improve prognosis and survival rate. This article reviews the progress in the treatment of MLL-rearranged leukemia, and highlights the progress and potential of targeted therapy in recent years. \n \n \nKey words: \nLeukemia; Gene rearrangement; Antineoplastic combined chemotherapy protocols; Hematopoietic stem cell transplantation; Molecular targeted therapy; Immunotherapy; MLL gene","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"42 1","pages":"165-169"},"PeriodicalIF":0.0000,"publicationDate":"2019-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.02.014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
MLL-rearranged leukemia is caused by rearrangement of the MLL gene located on chromosome 11q23, which is one of the common types in childhood leukemia. It can be clinically manifested as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome, and treatment-related leukemia. At present, the treatments of MLL-rearranged leukemia are combined chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT). The survival rate has been improved, but the outcomes and prognosis of most MLL-rearrangement leukemia are not excellent. Targeted therapy and immunotherapy are expected to become new treatments for the disease, which improve prognosis and survival rate. This article reviews the progress in the treatment of MLL-rearranged leukemia, and highlights the progress and potential of targeted therapy in recent years.
Key words:
Leukemia; Gene rearrangement; Antineoplastic combined chemotherapy protocols; Hematopoietic stem cell transplantation; Molecular targeted therapy; Immunotherapy; MLL gene
期刊介绍：
The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
